Glycomine is developing orphan drugs for serious rare monogenic disorders of metabolism and protein misfolding for which no other therapeutic options exist. The company\'s approach is to combine replacement therapies - substrates, enzymes, or proteins - with intracellular delivery vehicles consisting of bio-nanomaterials or ligands that target the molecules to the cell interior of clinically relevant organs.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 11/16/16 | $12,000,000 | Series A |
Chiesi Ventures Sanderling Ventures | undisclosed |
| 06/23/21 | $68,000,000 | Series B |
Abingworth Asahi Kasai Ventures Chiesi Ventures Mission BioCapital Novo Holdings Remiges Ventures RiverVest Venture Partners Sanderling Ventures Sanofi Ventures | undisclosed |
| 04/16/25 | $115,000,000 | Series C |
Abingworth abrdn Advent Life Sciences Asahi Kasai Ventures Chiesi Ventures CTI Life Sciences Novo Holdings Remiges Ventures RiverVest Venture Partners Sanderling Ventures Sanofi Ventures | undisclosed |
